HomeCompareXPMSX vs ABBV

XPMSX vs ABBV: Dividend Comparison 2026

XPMSX yields 1.16% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.4K in total portfolio value
10 years
XPMSX
XPMSX
● Live price
1.16%
Share price
$59.64
Annual div
$0.69
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.3K
Annual income
$125.33
Full XPMSX calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — XPMSX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXPMSXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XPMSX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XPMSX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XPMSX
Annual income on $10K today (after 15% tax)
$98.80/yr
After 10yr DRIP, annual income (after tax)
$106.53/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, ABBV beats the other by $21,419.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XPMSX + ABBV for your $10,000?

XPMSX: 50%ABBV: 50%
100% ABBV50/50100% XPMSX
Portfolio after 10yr
$62.5K
Annual income
$12,725.06/yr
Blended yield
20.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

XPMSX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XPMSX buys
0
ABBV buys
0
No recent congressional trades found for XPMSX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXPMSXABBV
Forward yield1.16%3.09%
Annual dividend / share$0.69$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$21.3K$103.7K
Annual income after 10y$125.33$25,324.79
Total dividends collected$1.2K$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: XPMSX vs ABBV ($10,000, DRIP)

YearXPMSX PortfolioXPMSX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,816$116.23$11,555$434.96$739.00ABBV
2$11,691$117.49$13,485$635.47$1.8KABBV
3$12,628$118.69$15,933$937.67$3.3KABBV
4$13,632$119.81$19,118$1,400.80$5.5KABBV
5$14,707$120.87$23,384$2,125.24$8.7KABBV
6$15,858$121.88$29,290$3,286.81$13.4KABBV
7$17,091$122.82$37,776$5,205.38$20.7KABBV
8$18,411$123.71$50,495$8,488.44$32.1KABBV
9$19,824$124.55$70,497$14,346.44$50.7KABBV
10$21,337$125.33$103,718$25,324.79$82.4KABBV

XPMSX vs ABBV: Complete Analysis 2026

XPMSXStock

A non‑diversified, closed‑end management investment company that invests in private market assets with the objective of long-term capital appreciation and providing current income through quarterly distributions

Full XPMSX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this XPMSX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XPMSX vs SCHDXPMSX vs JEPIXPMSX vs OXPMSX vs KOXPMSX vs MAINXPMSX vs JNJXPMSX vs MRKXPMSX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.